Alumis Inc. has disclosed a stock sale by Chief Business & Strategy Officer Roy C. Hardiman, which took place on November 2, 2026. This transaction is significant as it reflects the company's approach to managing tax obligations associated with vested stock units.

Hardiman sold 652 shares of common stock at a price of $6.52 each, totaling approximately $4,253.04. This sale was conducted under the issuer's policy requiring sell-to-cover transactions to satisfy tax obligations incurred from the vesting of restricted stock units granted previously.

Background

Alumis Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company, listed on the Nasdaq under the ticker ALMS, is based in South San Francisco, California. Recent filings indicate that Alumis has been active in managing its stock and financial strategies, with multiple Form 4 submissions on November 4, 2026.

What the Filing Says

The filing reveals, "The sale reported on this Form 4 was effected pursuant to the Issuer's policy requiring sell-to-cover to satisfy tax obligations of the Reporting Person incurred with the vesting and settlement of restricted stock units granted on July 29, 2025, and does not represent a discretionary sale by the Reporting Person." This highlights the structured approach Alumis takes regarding stock transactions.

Impact

This transaction may affect various stakeholders, including shareholders and potential investors, as it underscores the company's financial management strategies. The pharmaceutical preparations industry may also observe this event, considering how similar companies handle stock sales and tax obligations.

What's Next

The filing does not say what happens next.